Fundz

VectorY Therapeutics raises €74.5 million ($83.5 million) to advance its clinical and preclinical pipeline. The funding includes new investors like Angelini Ventures and returning investors such as Forbion and EQT Life Sciences.

PRIVATENov 11, 2026

Amount Raised

€74.5 Million

Round Type

Venture

BiotechnologyHealth CareTherapeutics

Investors

InsightMRL VenturesEQT Life SciencesForbionEibInvest NlAngelini Ventures

Description

VectorY Therapeutics, a biotechnology company focused on neurodegenerative diseases, has secured €74.5 million in new financing. The funds will be used to further develop its clinical and preclinical pipeline. This round includes participation from various new and returning investors. The involvement of prominent investors highlights the confidence in VectorY's innovative approach.

Quick answer

VectorY raised €74.5 Million in a funding round, dated November 11, 2026. Investors: Insight, MRL Ventures, EQT Life Sciences, Forbion, Eib, Invest Nl and Angelini Ventures.

How much did VectorY raise?
VectorY raised €74.5 Million in a funding round on November 11, 2026.
Who invested in VectorY?
Insight, MRL Ventures, EQT Life Sciences, Forbion, Eib, Invest Nl and Angelini Ventures are named as investors in this round.
What does VectorY do?
VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases.
Where is VectorY based and how big is it?
Fundz records about 82 employees.
Who are the decision-makers at VectorY?
Fundz holds 1 contact at VectorY. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as VectorY that raised within 45 days of this round, from Fundz verified event records.

  • Oyster Therapeutics raised $60M (Series A) on November 10, 2026.
  • SRTD biotech raised $35M (Seed) on November 9, 2026.
  • BioVie raised $4.7M (Post-IPO Equity) on November 6, 2026.
  • Alethio raised $90M (Series A) on November 5, 2026.
  • Biograil raised $22M on November 4, 2026.
  • MyoPax raised an undisclosed amount (Pre-Seed) on November 4, 2026.

Who to call at VectorY, and when

A new round usually means VectorY is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day VectorY raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at VectorY, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at VectorY. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

VectorY

About

VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases. With R&D and manufacturing facilities in Amsterdam, VectorY develops proprietary & partnered programs based on its novel AAV-based vectorized antibody & gene therapy platform. Product candidates are based on new vector technologies, which will enable the next generation of highly scalable manufacturing processes within VectorY’s own manufacturing facilities. Our manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands, with the capability to deliver suspension based AAV viral vector manufacturing of up to 2000L for both clinical and commercial supply.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment VectorY raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for VectorY's next move

See what Strategic adds

VectorY raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.